Last Updated: May 25, 2026

LONHALA MAGNAIR KIT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Lonhala Magnair Kit, and when can generic versions of Lonhala Magnair Kit launch?

Lonhala Magnair Kit is a drug marketed by Sumitomo Pharma Am and is included in one NDA. There are nine patents protecting this drug.

This drug has sixty-nine patent family members in fourteen countries.

The generic ingredient in LONHALA MAGNAIR KIT is glycopyrrolate. There are seventeen drug master file entries for this compound. Sixty-two suppliers are listed for this compound. Additional details are available on the glycopyrrolate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Lonhala Magnair Kit

A generic version of LONHALA MAGNAIR KIT was approved as glycopyrrolate by AM REGENT on July 23rd, 1986.

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for LONHALA MAGNAIR KIT?
  • What are the global sales for LONHALA MAGNAIR KIT?
  • What is Average Wholesale Price for LONHALA MAGNAIR KIT?

US Patents and Regulatory Information for LONHALA MAGNAIR KIT

LONHALA MAGNAIR KIT is protected by nine US patents.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sumitomo Pharma Am LONHALA MAGNAIR KIT glycopyrrolate SOLUTION;INHALATION 208437-001 Dec 5, 2017 DISCN Yes No 10,940,110 ⤷  Start Trial Y ⤷  Start Trial
Sumitomo Pharma Am LONHALA MAGNAIR KIT glycopyrrolate SOLUTION;INHALATION 208437-001 Dec 5, 2017 DISCN Yes No 9,168,556 ⤷  Start Trial Y ⤷  Start Trial
Sumitomo Pharma Am LONHALA MAGNAIR KIT glycopyrrolate SOLUTION;INHALATION 208437-001 Dec 5, 2017 DISCN Yes No 9,789,270 ⤷  Start Trial Y ⤷  Start Trial
Sumitomo Pharma Am LONHALA MAGNAIR KIT glycopyrrolate SOLUTION;INHALATION 208437-001 Dec 5, 2017 DISCN Yes No 10,688,518 ⤷  Start Trial Y ⤷  Start Trial
Sumitomo Pharma Am LONHALA MAGNAIR KIT glycopyrrolate SOLUTION;INHALATION 208437-001 Dec 5, 2017 DISCN Yes No 10,744,277 ⤷  Start Trial Y ⤷  Start Trial
Sumitomo Pharma Am LONHALA MAGNAIR KIT glycopyrrolate SOLUTION;INHALATION 208437-001 Dec 5, 2017 DISCN Yes No 10,376,661 ⤷  Start Trial Y ⤷  Start Trial
Sumitomo Pharma Am LONHALA MAGNAIR KIT glycopyrrolate SOLUTION;INHALATION 208437-001 Dec 5, 2017 DISCN Yes No 9,604,018 ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for LONHALA MAGNAIR KIT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sumitomo Pharma Am LONHALA MAGNAIR KIT glycopyrrolate SOLUTION;INHALATION 208437-001 Dec 5, 2017 7,458,372 ⤷  Start Trial
Sumitomo Pharma Am LONHALA MAGNAIR KIT glycopyrrolate SOLUTION;INHALATION 208437-001 Dec 5, 2017 6,962,151 ⤷  Start Trial
Sumitomo Pharma Am LONHALA MAGNAIR KIT glycopyrrolate SOLUTION;INHALATION 208437-001 Dec 5, 2017 7,931,212 ⤷  Start Trial
Sumitomo Pharma Am LONHALA MAGNAIR KIT glycopyrrolate SOLUTION;INHALATION 208437-001 Dec 5, 2017 7,316,067 ⤷  Start Trial
Sumitomo Pharma Am LONHALA MAGNAIR KIT glycopyrrolate SOLUTION;INHALATION 208437-001 Dec 5, 2017 8,511,581 ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for LONHALA MAGNAIR KIT

See the table below for patents covering LONHALA MAGNAIR KIT around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 2708219 Élément d'ouverture pour ouvrir une ampoule dans un dispositif de génération d'aérosol et dispositif de génération d'aérosol comprenant l'élément d'ouverture (Opening element for opening an ampoule in an aerosol generation device and aerosol generation device comprising the opening element) ⤷  Start Trial
Japan 4589862 ⤷  Start Trial
Spain 2809565 ⤷  Start Trial
Austria 453424 ⤷  Start Trial
European Patent Office 2062608 Ampoule unidirectionnelle pour un dispositif de production d'aérosols (Single use ampoule for a device to create aerosols) ⤷  Start Trial
Australia 1698301 ⤷  Start Trial
New Zealand 587561 ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for LONHALA MAGNAIR KIT

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2435024 21C1020 France ⤷  Start Trial PRODUCT NAME: COMBINAISON DE FORMOTEROL (Y COMPRIS LES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI), GLYCOPYRROLATE (Y COMPRIS LES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI) ET BUDESONIDE (Y COMPRIS LES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI); REGISTRATION NO/DATE: EU/1/20/1498 20201210
2435025 19C1040 France ⤷  Start Trial PRODUCT NAME: COMBINAISON DE GLYCOPYRROLATE (Y COMPRIS TOUS SELS, ESTERS, ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI) ET DE FORMOTEROL (Y COMPRIS TOUS SELS, ESTERS, ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI); NAT. REGISTRATION NO/DATE: EU/1/18/1339 20181220; FIRST REGISTRATION: - EU/1/18/1339 20181220
2435025 2019C/532 Belgium ⤷  Start Trial PRODUCT NAME: UNE COMBINAISON DE GLYCOPYRROLATE (INCLUANT LES SELS ACCEPTABLES PHARMACEUTIQUEMENT, LES ESTERS, LES ENANTIOMERES OU LES AUTRES DERIVES DE CECI) ET DE FORMOTEROL (INCLUANT LES SELS ACCEPTABLES PHARMACEUTIQUEMENT, LES ESTERS, LES ENANTIOMERES OU LES AUTRES DERIVES DE CECI); AUTHORISATION NUMBER AND DATE: EU/1/18/1339 20181220
2435024 2021C/518 Belgium ⤷  Start Trial PRODUCT NAME: UNE COMBINAISON DE FORMOTEROL (Y COMPRIS TOUS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES), GLYCOPYRROLATE (Y COMPRIS TOUS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES) ET BUDESONIDE (Y COMPRIS TOUS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES); AUTHORISATION NUMBER AND DATE: EU/1/20/1498 20201210
2435024 2190014-7 Sweden ⤷  Start Trial PRODUCT NAME: A COMBINATION OF FORMOTEROL INCLUDING ANY PHARMACEUUTICALLY ACCEPTABLE SALTS, ESTERS, OR SOLVATES THEREOF, GLYCOPYRROLATE INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, OR SOLVATES THEREOF, AND BUDESONIDE INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALT, ESTERS ORSOLVATES THEREOF; REG. NO/DATE: EU/1/20/1498 20201210
2435024 SPC/GB21/029 United Kingdom ⤷  Start Trial PRODUCT NAME: A COMBINATION OF FORMOTEROL, INCLUDING PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS AND SOLVATES THEREOF, GLYCOPYRROLATE, INCLUDING PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS AND SOLVATES THEREOF, AND BUDESONIDE INCLUDING PHARMACEUTICALLY ACCEPTABLE SALTS, ES; REGISTERED: UK EU/1/20/1498 (NI) 20201210; UK PLGB 17901/0352-001 20201210
2435024 202140009 Slovenia ⤷  Start Trial PRODUCT NAME: COMBINATION OF FORMOTEROL (INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, SOLVATES OR ENANTIOMERS THEREOF), GLYCOPYRROLATE (INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, SOLVATES OR ENANTIOMERS THEREOF) AND BUDESONIDE (INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, SOLVATES OR ENANTIOMERS THEREOF); NATIONAL AUTHORISATION NUMBER: EU/1/20/1498; DATE OF NATIONAL AUTHORISATION: 20201209; AUTHORITY FOR NATIONAL AUTHORISATION: EU
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Market Dynamics and Financial Trajectory for LONHALA MAGNAIR Kit

Last updated: February 19, 2026

What is the LONHALA MAGNAIR Kit?

The LONHALA MAGNAIR Kit (glycopyrrolate inhalation aerosol) is an FDA-approved bronchodilator for maintenance treatment of COPD (Chronic Obstructive Pulmonary Disease). It uses dry powder inhalation technology and was approved in the U.S. in August 2020. The drug is marketed by Sunovion Pharmaceuticals.

Market Landscape

COPD Treatment Market Overview

  • The global COPD market was valued at approximately $16.4 billion in 2021.
  • CAGR from 2022-2027 estimated at 4.8% (Research and Markets, 2022).
  • Key therapies include inhaled corticosteroids, LABAs, LAMAs, and combination inhalers.
  • LAMAs (Long-Acting Muscarinic Antagonists) comprise a significant portion.

Competitive Position

  • LONHALA MAGNAIR competes directly against other LAMAs like Spiriva (tiotropium) and Tudorza (aclidinium).
  • Spiriva remained the market leader with ~$3.4 billion in sales in 2021 (IQVIA, 2022).
  • LONHALA's unique inhaler device and delivery method aim to improve adherence.

Market Penetration

  • Initial launch in the U.S. began in late 2020.
  • Market share has been constrained by established competitors.
  • Adoption impacted by physician prescribing habits and formulary placements.

Financial Trajectory

Revenue Generation

  • Sunovion reported LONHALA MAGNAIR sales of approximately $100 million in North America for FY2022.
  • Projected global sales are limited by market penetration and patent exclusivity.

Revenue Drivers

  • Growing COPD prevalence (approx. 200 million cases worldwide).
  • Increasing awareness of LAMA-based therapies.
  • Expansion into European and Asian markets anticipated, depending on regulatory approvals.

Pricing and Reimbursement

  • Wholesale acquisition cost (WAC) in the U.S. set at around $300 per inhaler.
  • Reimbursement coverage varies; commercial plans favor established brands.
  • Price sensitivity influences prescribing volume.

Future Revenue Potential

Year Estimated Sales (USD millions) Key Factors
2023 150 – 200 Increased market penetration, expanded access
2025 300 – 450 Expanded geographic footprint, formulary wins
2030 500+ Patients with COPD using LAMAs, competitive positioning

R&D & Investment Outlook

  • Continued investment in marketing, efficacy studies, and market expansion.
  • Strategic partnerships for distribution in emerging markets.

Regulatory and Policy Considerations

  • Patent life estimated to extend until 2030.
  • Future formulations or combination products under development.
  • Reimbursement policies evolving with new COPD guidelines.

Risks and Uncertainties

  • Market competition from established LAMAs and combination therapies.
  • Pricing pressures due to healthcare cost containment.
  • Regulatory delays in international markets.
  • Technological advances in inhaler device development.

Key Takeaways

  • LONHALA MAGNAIR has a niche in the COPD maintenance therapy market with modest current sales.
  • Growth relies on increasing COPD prevalence, formulary placements, and geographic expansion.
  • Revenue projections suggest potential to reach hundreds of millions in annual sales by 2025-2030.
  • Competitive landscape remains intense; differentiation hinges on device preference and adherence.

FAQs

What is the primary advantage of LONHALA MAGNAIR?
Its dry powder inhaler device improves ease of use compared to traditional inhalers.

How does LONHALA MAGNAIR compare price-wise?
It has a similar price point to other LAMAs, around $300 per inhaler, affecting affordability and reimbursement.

What are the main competitors?
Spiriva (tiotropium), Tudorza (aclidinium), and other LAMAs.

Is LONHALA MAGNAIR approved outside the U.S.?
Yes. It has regulatory submissions pending or approved in select European and Asian countries.

What factors could accelerate sales growth?
Expanding into new markets, formulary acceptance, clinical evidence supporting superiority, and improving patient adherence.

References

  1. Research and Markets. (2022). Global COPD Market Forecast 2022-2027.
  2. IQVIA. (2022). Prescription Drug Sales Data.
  3. U.S. Food and Drug Administration. (2020). FDA Approval for LONHALA MAGNAIR.
  4. Sunovion Pharmaceuticals. (2022). Annual Reports.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.